Sun Pharmaceutical Industries achieved a significant milestone on December 18 as its market capitalisation (m-cap) crossed the Rs 3-lakh-crore threshold during afternoon trading. This surge in m-cap was attributed to investors turning towards defensive plays in a market displaying subdued dynamics.
The pharma giant’s stock experienced a notable uptick, climbing 2.5 percent to reach a 52-week high of Rs 1,267 per share on December 18. Throughout the year, Sun Pharma shares have exhibited robust growth, recording a surge of over 26 percent, outperforming the benchmark Sensex, which witnessed a 17 percent rise in the same period.
On December 18 alone, approximately 1.5 million equity shares changed hands on both the BSE and NSE, slightly below the one-month average of 1.9 million equity shares, indicative of the heightened investor interest in Sun Pharma.
As of 1:24 pm, Sun Pharma shares continued their upward trajectory, trading 1.68% higher at ₹1,256.50. The breach of the Rs 3-lakh-crore market cap demonstrates the company’s resilience and attractiveness to investors seeking stability and growth in a dynamic market environment.
